Co-Authors
This is a "connection" page, showing publications co-authored by Lorenzo Zammarchi and Laura Maggi.
Connection Strength
0.289
-
Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib. Am J Hematol. 2021 11 01; 96(11):E408-E410.
Score: 0.060
-
First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19. J Clin Invest. 2021 06 15; 131(12).
Score: 0.059
-
Cell-mediated and humoral adaptive immune responses to SARS-CoV-2 are lower in asymptomatic than symptomatic COVID-19 patients. Eur J Immunol. 2020 Dec; 50(12):2013-2024.
Score: 0.057
-
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest. 2020 09 01; 130(9):4694-4703.
Score: 0.056
-
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. Leukemia. 2021 04; 35(4):1121-1133.
Score: 0.056